Independent Research on Mutual Funds, Stocks & IPOs for Indian Investors

Sai Parenterals is a Telangana-based diversified pharmaceutical formulations company with capabilities in R&D, manufacturing, and commercialization. Operates two segments: Branded Generic Formulations and CDMO. Products span cardiovascular, neuropsychiatry, anti-diabetic, respiratory, antibiotics, gastroenterology, VMS, analgesics. Revenue grew 30% CAGR FY23–25. PAT grew 82% CAGR. Expanding into Australia via proposed acquisition of Noumed Pharmaceuticals. Revenue ₹164 Cr (FY25) vs ₹155 Cr (FY24), PAT ₹14.5 Cr (FY25) vs ₹8.4 Cr (FY24). Promoter holding: pre-IPO 61.2%, post-IPO 51.2%.